DOCSLIB.ORG

Gene Repression by KRAB Zinc Finger Proteins

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gene Repression by KRAB Zinc Finger Proteins MECHANISMS OF TRANSCRIPTIONAL REGULATION: GENE REPRESSION BY KRAB ZINC FINGER PROTEINS AND GENE INDUCTION BY ESTROGEN RECEPTOR beta by SMITHA P. SRIPATHY Submitted in partial fulfillment of the requirements for a degree in Doctor of Philosophy. Dissertation advisors: David C. Schultz and Monica M. Montano Department of Pharmacology CASE WESTERN RESERVE UNIVERSITY January 2009 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Smitha P. Sripathy for the Pharmacology degree *. (signed) Ruth A. Keri (chair of the committee) John J. Mieyal David Samols Monica M. Montano (date) 07/15/08 *We also certify that written approval has been obtained for any proprietary material contained therein. i Table of Contents List of figures and tables iii Acknowledgement viii List of abbreviations 1 Abstract 3 Chapter I Transcriptional regulation: An overview 6 Gene repression by KRAB zinc finger proteins Chapter II Introduction, review of literature and 17 statement of purpose Chapter III Mechanism of transcriptional repression of 35 KRAB zfps Chapter IV Summary and future directions 117 Gene induction by estrogen receptor beta Chapter V Introduction, review of literature and 134 statement of purpose Chapter VI Mechanism of transcriptional induction of 159 EpRE-genes by ERβ Chapter VII Summary and future directions 201 Bibliography 211 ii List of Tables and Figures Figure I-1 Hox gene clusters regulate head-tail morphology 9 in humans Table I-1 A minimal classification of transcriptional 11 coregulators Figure II-1 Representation of a complex between DNA and 19 the ZIF268 protein, containing 3 zinc finger motifs. Figure II-2 Sequence alignment of the KRAB domain from 22 different KRAB–ZFPs Figure II-3 Schematic representation of the TIF1 protein 26 family Figure III-1 KAP1 is required for KRAB-mediated repression 75 Figure III-2 Stable depletion of KAP1 in HEK293 cells. 77 Figure III-3 Direct tethering of KAP1 to DNA is sufficient to 79 represses transcription Figure III-4 The corepressor activity of KAP1 depends on its 81 interaction with HP1 and a functional PHD finger and bromodomain Figure III-5 Establishment of cell lines with a hormone- 83 iii regulatable reporter transgene Figure III-6 Characterization of cell lines with a chromatinized 85 5XGAL4-TK-luciferase transgene. Figure III-7 Hormone dependent repression of chromatinized 87 luciferase transgenes by ERHBDTM-GAL4 fused repressor proteins Figure III-8 Hormone-dependent repression of the chromatin 89 template by ERHBD-GAL4-KRAB requires KAP1 Figure III-9 Hormone-dependent repression Kinetics of 91 ERHBD-GLA4-KRAB wildtype and mutant cells Figure III-10 Hormone-dependent KRAB repression is 93 dependent on KAP1. Figure III-11 KRAB mediated repression of a chromatin 95 template is independent of TIF1α and TIF1γ. Figure III-12 Hormone-dependent repression of chromatin 97 templates by ERHBD-GAL4-KAP1 Figure III-13 Kinetics of hormone-dependent repression of 99 chromatin templates by ERHBD-GAL4-KAP1 wildtype and mutants Figure III-14 Expression of the KAP1 repression machinery 101 Figure III-15 Chromatin immunoprecipitation analysis of a 103 iv luciferase transgene repressed by ERHBD-GAL4- KAP1. Figure III-16 Hormone dependent repression mediated by 105 KAP1 involves hypoacetylation of histone H3 K9 of the transgenic reporter Figure III-17 Disruption of the KAP1-HP1 interaction fails to 107 induce hormone-dependent changes in RNA polymerase II recruitment, histone occupancy, and histone modifications Figure III-18 Chromatin immnoprecipitation analysis of 109 hormone-dependent changes in mediated by ERHBDTM-GAL4-KAP1, mutated in either the PHD finger or bromodomain, respectively Figure III-19 Hormone-dependent KRAB repression of a 111 chromatin template requires KAP1, HP1, and SETDB1. Figure III-20 Transient knockdown of HP1β expression and its 113 effect on KRAB mediated repression. Figure IV-1 Model of KRAB/KAP1 mediated repression 119 v mechanism Figure V-1 Metabolic activation and deactivation of estradiol 140 Figure V-2 Representation of cDNA variants that encode ERβ 151 isoforms Figure VI-1 hPMC2 interacts directly with ERβ and is involved 182 in mediating Tamoxifen-dependent decrease in ODD levels Figure VI-2 Tamoxifen-dependent recruitment of coactivators 184 to the EpRE sequence of NQO1 Figure VI-3 Both ERβ and hPMC2 are required for tamoxifen- 186 mediated increase in antioxidative enzyme expression and protection against ODD Figure VI-4 Tamoxifen-dependent recruitment of coactivators 188 to the EpRE sequence of NQO1 requires both ERβ and hPMC2. Figure VI-5 Tamoxifen treatment induces increased 190 transcription of antioxidative enzyme levels. Figure VI-6 Knockdown of PARP-1 attenuates tamoxifen- 192 dependent increase in the expression of vi antioxidative enzymes Figure VI-7 PARP-1 down regulation does not significantly 194 affect basal expression levels of antioxidative enzymes. Figure VI-8 Ligand dependent recruitment of ERβ and hPMC2 196 to the ERE region Table VI-1 Sequence of DNA oligos cloned into pSuper- 198 QRshRNA, pSuper-hPMC2shRNA and PCDNA- hPMC2 569miR plasmids respectively. Table VI-2 Primer sequences used in the various PCR 199 reactions described in Chapter VI Table VI-3 Antibodies used in Chapter VI 200 Figure VII-1 Induction of antioxidative genes by tamoxifen 202 liganded ERβ vii Acknowledgements First and foremost I would like to thank my parents who instilled in me a sense of curiosity and wonder, encouraged me to explore the world around and shared in my enthusiasm. These qualities led me to pursue science as a career and were a major factor in my decision to do a Ph.D. They have been a source of constant support and encouragement all through the making of this dissertation. I extend my sincere thanks to my first thesis advisor Dr. David Schultz for starting me out on the path of scientific thinking. I learnt to critically analyze experiments, both others and mine, and think about more than just the most obvious interpretation of a result. He had an invaluable teaching tool that was very effective in getting the message across to me, he simply taught by example. His dedication to order, method, and attention to detail while planning and conducting experiments has made me realize that the “devil is indeed in the details”. I thank him for providing me with the foundations necessary for any student of science. It is a pleasure to thank my current thesis advisor, Dr. Monica Montano whose support and encouragement was key to the completion of this dissertation. I thank her generosity in letting me join her lab and the independence she gave me in conducting my project. She has always been ready viii to discuss any concerns regarding not just my dissertation work, but just about anything. Her open and hands off approach has helped me gain confidence in my ability to successfully generate and test hypotheses, a critical quality in any scientist. It has been a lot of fun being in Monica’s lab, her humor and ready sense of wit has made for many a lively conversation in the lab. In more than 5 years that it took to complete this dissertation, I have been fortunate to meet some wonderful people who have become great friends. I would especially like to acknowledge Bonnie Gorzelle, Ndiya Ogba and Laura O’ Donnell. Bonnie has been a very patient listener, her calmness has helped me many a times in not getting hyper over my negative results (though she is completely unaware of it). I am lucky to have a person like Ndiya for a friend. She has been a great support for me in the lab, a very good source to discuss not only trouble shooting strategies or just about anything. I thank her for being who she is and also for the umpteen number of times she has driven me all over Cleveland at very short notices. Her timely help has enabled me to actually focus on my experiments. Last but not the least, it is with joy that I thank Laura. She is just a great person to be around with and a good friend. I thank her for helping me seek reagents around the lab for the nth time without the slightest trace of irritation. I thank her for her constant bright smile and helping nature that endears her to everyone. Any acknowledgement of Laura is not complete ix without the mention of her amazing cakes and cookies which were frequently to be found outside the lab. x List of Abbreviations 4-OHT 4-Hydroxytamoxifen 8-OHdG 8-Hydroxydeoxyguanine APL Acute Promyelocytic Leukemia ATRA All trans retinoic acid CE Catechol estrogen CE-SQ Catechol estrogen-semiquinone CE-Q Catechol estrogen quinone ChIP chromatin immunoprecipitation DBD DNA binding domain DBS DNA binding site E2 17β-estradiol EpRE electrophile response element ERα Estrogen receptor alpha ERβ Estrogen receptor beta ERE Estrogen response element ERHBD Estrogen receptor hormone binding domain GCSh Gamma-glutamylcysteine Synthase, heavy subunit GSTpi Glutathione-S-transferase H3K9 Histone H3 Lysine 9 HDAC Histone deacetylase 1 HP1 Heterochromatin protein 1 hPMC2 Human homolog of Xenopus laevis prevention of mitotic catastrophe 2 IP Immunoprecipitation KAP1 KRAB associated protein 1 KRAB Kruppel associated box ODD Oxidative DNA damage PHD plant homeodomain QR Quinone reductase RBCC RING B-box Coiled-Coil RING Really Interesting New Gene SETDB1 SET domain bifurcated 1 TOT trans-Hydroxytamoxifen TIF1 Transcription intermediary factor 1 Zfp zinc finger protein 2 Mechanisms Of Transcriptional Regulation: Gene Repression By KRAB Zinc Finger Proteins And Gene Induction By Estrogen Receptor beta Abstract by SMITHA P. SRIPATHY DNA binding transcription factors are key players in the dynamic regulation of distinct gene expression programs, essential for maintenance of cell physiology and differentiation. Transcription factors either activate or repress transcription by sequence-selective binding to cis DNA elements and subsequent recruitment of distinct coregulator complexes.
Load more

Recommended publications
  • The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
    Published OnlineFirst October 26, 2016; DOI: 10.1158/2159-8290.CD-15-1263 RESEARCH ARTICLE The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer Jennifer L. Bishop1, Daksh Thaper1,2, Sepideh Vahid1,2, Alastair Davies1, Kirsi Ketola1, Hidetoshi Kuruma1, Randy Jama1, Ka Mun Nip1,2, Arkhjamil Angeles1, Fraser Johnson1, Alexander W. Wyatt1,2, Ladan Fazli1,2, Martin E. Gleave1,2, Dong Lin1, Mark A. Rubin3, Colin C. Collins1,2, Yuzhuo Wang1,2, Himisha Beltran3, and Amina Zoubeidi1,2 ABSTRACT Mechanisms controlling the emergence of lethal neuroendocrine prostate cancer (NEPC), especially those that are consequences of treatment-induced suppression of the androgen receptor (AR), remain elusive. Using a unique model of AR pathway inhibitor–resistant prostate cancer, we identified AR-dependent control of the neural transcription factor BRN2 (encoded by POU3F2) as a major driver of NEPC and aggressive tumor growth, both in vitro and in vivo. Mecha- nistic studies showed that AR directly suppresses BRN2 transcription, which is required for NEPC, and BRN2-dependent regulation of the NEPC marker SOX2. Underscoring its inverse correlation with clas- sic AR activity in clinical samples, BRN2 expression was highest in NEPC tumors and was significantly increased in castration-resistant prostate cancer compared with adenocarcinoma, especially in patients with low serum PSA. These data reveal a novel mechanism of AR-dependent control of NEPC and suggest that targeting BRN2 is a strategy to treat or prevent neuroendocrine differentiation in prostate tumors. SIGNIFICANCE: Understanding the contribution of the AR to the emergence of highly lethal, drug- resistant NEPC is critical for better implementation of current standard-of-care therapies and novel drug design.
    [Show full text]
  • Core Transcriptional Regulatory Circuitries in Cancer
    Oncogene (2020) 39:6633–6646 https://doi.org/10.1038/s41388-020-01459-w REVIEW ARTICLE Core transcriptional regulatory circuitries in cancer 1 1,2,3 1 2 1,4,5 Ye Chen ● Liang Xu ● Ruby Yu-Tong Lin ● Markus Müschen ● H. Phillip Koeffler Received: 14 June 2020 / Revised: 30 August 2020 / Accepted: 4 September 2020 / Published online: 17 September 2020 © The Author(s) 2020. This article is published with open access Abstract Transcription factors (TFs) coordinate the on-and-off states of gene expression typically in a combinatorial fashion. Studies from embryonic stem cells and other cell types have revealed that a clique of self-regulated core TFs control cell identity and cell state. These core TFs form interconnected feed-forward transcriptional loops to establish and reinforce the cell-type- specific gene-expression program; the ensemble of core TFs and their regulatory loops constitutes core transcriptional regulatory circuitry (CRC). Here, we summarize recent progress in computational reconstitution and biologic exploration of CRCs across various human malignancies, and consolidate the strategy and methodology for CRC discovery. We also discuss the genetic basis and therapeutic vulnerability of CRC, and highlight new frontiers and future efforts for the study of CRC in cancer. Knowledge of CRC in cancer is fundamental to understanding cancer-specific transcriptional addiction, and should provide important insight to both pathobiology and therapeutics. 1234567890();,: 1234567890();,: Introduction genes. Till now, one critical goal in biology remains to understand the composition and hierarchy of transcriptional Transcriptional regulation is one of the fundamental mole- regulatory network in each specified cell type/lineage.
    [Show full text]
  • PAX3–FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain
    Published OnlineFirst April 26, 2017; DOI: 10.1158/2159-8290.CD-16-1297 RESEARCH ARTICLE PAX3–FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability Berkley E. Gryder 1 , Marielle E. Yohe 1 , 2 , Hsien-Chao Chou 1 , Xiaohu Zhang 3 , Joana Marques 4 , Marco Wachtel4 , Beat Schaefer 4 , Nirmalya Sen 1 , Young Song 1 , Alberto Gualtieri 5 , Silvia Pomella 5 , Rossella Rota5 , Abigail Cleveland 1 , Xinyu Wen 1 , Sivasish Sindiri 1 , Jun S. Wei 1 , Frederic G. Barr 6 , Sudipto Das7 , Thorkell Andresson 7 , Rajarshi Guha 3 , Madhu Lal-Nag 3 , Marc Ferrer 3 , Jack F. Shern 1 , 2 , Keji Zhao8 , Craig J. Thomas 3 , and Javed Khan 1 Downloaded from cancerdiscovery.aacrjournals.org on September 29, 2021. © 2017 American Association for Cancer Research. 16-CD-16-1297_p884-899.indd 884 7/20/17 2:21 PM Published OnlineFirst April 26, 2017; DOI: 10.1158/2159-8290.CD-16-1297 ABSTRACT Alveolar rhabdomyosarcoma is a life-threatening myogenic cancer of children and ado- lescent young adults, driven primarily by the chimeric transcription factor PAX3–FOXO1. The mechanisms by which PAX3–FOXO1 dysregulates chromatin are unknown. We fi nd PAX3–FOXO1 repro- grams the cis -regulatory landscape by inducing de novo super enhancers. PAX3–FOXO1 uses super enhancers to set up autoregulatory loops in collaboration with the master transcription factors MYOG, MYOD, and MYCN. This myogenic super enhancer circuitry is consistent across cell lines and primary tumors. Cells harboring the fusion gene are selectively sensitive to small-molecule inhibition of protein targets induced by, or bound to, PAX3–FOXO1-occupied super enhancers.
    [Show full text]
  • PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1 Alexandra Lacey1, Aline Rodrigues-Hoffman2, and Stephen Safe1
    Published OnlineFirst November 18, 2016; DOI: 10.1158/0008-5472.CAN-16-1546 Cancer Therapeutics, Targets, and Chemical Biology Research PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1 Alexandra Lacey1, Aline Rodrigues-Hoffman2, and Stephen Safe1 Abstract Alveolar rhabdomyosarcoma (ARMS) is a devastating pediatric PAX3-FOXO1A. Mechanistic investigations revealed a requirement disease driven by expression of the oncogenic fusion gene PAX3- for the NR4A1/Sp4 complex to bind GC-rich promoter regions FOXO1A. In this study, we report overexpression of the nuclear to elevate transcription of the PAX3-FOXO1A gene. In parallel, receptor NR4A1 in rhabdomyosarcomas that is sufficient to NR4A1 also regulated expression of b1-integrin, which with PAX3- drive high expression of PAX3-FOXO1A there. RNAi-mediated FOXO1A, contributed to tumor cell migration that was blocked by silencing of NR4A1 decreased expression of PAX3-FOXO1A and C-DIM/NR4A1 antagonists. Taken together, our results provide a its downstream effector genes. Similarly, cell treatment with the preclinical rationale for the use of NR4A1 small-molecule antago- NR4A1 small-molecule antagonists 1,1-bis(3-indolyl)-1-(p- nists to treat ARMS and other rhabdomyosarcomas driven by hydroxy or p-carbomethoxyphenyl)methane (C-DIM) decreased PAX3-FOXO1A. Cancer Res; 77(3); 1–10. Ó2016 AACR. Introduction activity for NR4A1. In contrast, NR4A1 exhibits tumor promoter activity (6, 7) in solid tumors. NR4A1 is also overexpressed in Rhabdomyosarcoma is the most common soft-tissue sarco- tumors from patients with breast, lung, pancreatic, colon, and ma that is primarily observed in children and adolescents and ovarian cancer and is a negative prognostic factor for patients with accounts for 50% of all pediatric cancers and 50% of soft-tissue breast, lung, and ovarian cancer (9–15).
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1 Alexandra Lacey1, Aline Rodrigues-Hoffman2, and Stephen Safe1
    Published OnlineFirst November 18, 2016; DOI: 10.1158/0008-5472.CAN-16-1546 Cancer Therapeutics, Targets, and Chemical Biology Research PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1 Alexandra Lacey1, Aline Rodrigues-Hoffman2, and Stephen Safe1 Abstract Alveolar rhabdomyosarcoma (ARMS) is a devastating pediatric PAX3-FOXO1A. Mechanistic investigations revealed a requirement disease driven by expression of the oncogenic fusion gene PAX3- for the NR4A1/Sp4 complex to bind GC-rich promoter regions FOXO1A. In this study, we report overexpression of the nuclear to elevate transcription of the PAX3-FOXO1A gene. In parallel, receptor NR4A1 in rhabdomyosarcomas that is sufficient to NR4A1 also regulated expression of b1-integrin, which with PAX3- drive high expression of PAX3-FOXO1A there. RNAi-mediated FOXO1A, contributed to tumor cell migration that was blocked by silencing of NR4A1 decreased expression of PAX3-FOXO1A and C-DIM/NR4A1 antagonists. Taken together, our results provide a its downstream effector genes. Similarly, cell treatment with the preclinical rationale for the use of NR4A1 small-molecule antago- NR4A1 small-molecule antagonists 1,1-bis(3-indolyl)-1-(p- nists to treat ARMS and other rhabdomyosarcomas driven by hydroxy or p-carbomethoxyphenyl)methane (C-DIM) decreased PAX3-FOXO1A. Cancer Res; 77(3); 1–10. Ó2016 AACR. Introduction activity for NR4A1. In contrast, NR4A1 exhibits tumor promoter activity (6, 7) in solid tumors. NR4A1 is also overexpressed in Rhabdomyosarcoma is the most common soft-tissue sarco- tumors from patients with breast, lung, pancreatic, colon, and ma that is primarily observed in children and adolescents and ovarian cancer and is a negative prognostic factor for patients with accounts for 50% of all pediatric cancers and 50% of soft-tissue breast, lung, and ovarian cancer (9–15).
    [Show full text]
  • Trim24 Targets Endogenous P53 for Degradation
    Trim24 targets endogenous p53 for degradation Kendra Alltona,b,1, Abhinav K. Jaina,b,1, Hans-Martin Herza, Wen-Wei Tsaia,b, Sung Yun Jungc, Jun Qinc, Andreas Bergmanna, Randy L. Johnsona,b, and Michelle Craig Bartona,b,2 aDepartment of Biochemistry and Molecular Biology, Program in Genes and Development, Graduate School of Biomedical Sciences and bCenter for Stem Cell and Developmental Biology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030; and cDepartment of Molecular and Cellular Biology, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030 Edited by Carol L. Prives, Columbia University, New York, NY, and approved May 15, 2009 (received for review December 23, 2008) Numerous studies focus on the tumor suppressor p53 as a protector regulator of p53 suggests that potential therapeutic targets to of genomic stability, mediator of cell cycle arrest and apoptosis, restore p53 functions remain to be identified. and target of mutation in 50% of all human cancers. The vast majority of information on p53, its protein-interaction partners and Results and Discussion regulation, comes from studies of tumor-derived, cultured cells Creation of a Mouse and Stem Cell Model for p53 Analysis. To where p53 and its regulatory controls may be mutated or dysfunc- facilitate analysis of endogenous p53 in normal cells, we per- tional. To address regulation of endogenous p53 in normal cells, formed gene targeting to create mouse embryonic stem (ES) we created a mouse and stem cell model by knock-in (KI) of a cells and mice (12), which express endogenously regulated p53 tandem-affinity-purification (TAP) epitope at the endogenous protein fused with a C-terminal TAP tag (p53-TAPKI, Fig.
    [Show full text]
  • In Mediating Transcriptional Activity of Androgen Receptor Splice Variants
    ROLE OF TRANSCRIPTIONAL ACTIVATION UNIT 5 (TAU5) IN MEDIATING TRANSCRIPTIONAL ACTIVITY OF ANDROGEN RECEPTOR SPLICE VARIANTS A THESIS SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY SARITA KUMARI MUTHA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE SCOTT DEHM & JIM McCARTHY DECEMBER 2012 © Sarita Kumari Mutha 2012 ACKNOWLEDGEMENTS I would like to thank the Dehm Lab: Scott Dehm, Yingming Li, Siu Chiu Chan, and Luke Brand for the support, discussions, journal clubs, and training. I would like to thank MCBD&G faculty Kathleen Conklin and Meg Titus for their support. Finally, I would also to acknowledge my committee Scott Dehm, Jim McCarthy, and Kaylee Schwertfeger for their time and support. i DEDICATION This thesis is dedicated to my mentor and advisor Scott Dehm. This work would not have been possible without his support. I am very grateful for my time under his mentorship and the opportunity to learn from him. ii ABSTRACT The standard treatment for advanced prostate cancer is chemical castration, which inhibits the activity of the androgen receptor (AR). Eventually, prostate cancer reemerges with a castration-resistant phenotype (CRPC) but still depends on AR signaling. One mechanism of AR activity in CRPC is the synthesis of AR splice variants, which lack the ligand binding domain. These splice variants function as constitutively active transcription factors that promote expression of endogenous AR target genes and support androgen independent prostate cancer cell growth. Previous work has shown transcriptional activation unit 5 (TAU5) is necessary for ligand independent activity of the full length AR in low or no androgen conditions and that this activation is mediated by the WHTLF motif.
    [Show full text]
  • Functional Impact of a Germline RET Mutation in Alveolar Rhabdomyosarcoma
    Downloaded from molecularcasestudies.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press Follow-up Report for CSHL Molecular Case Studies Functional impact of a germline RET mutation in alveolar rhabdomyosarcoma Mutant RET in alveolar rhabdomyosarcoma Noah E. Berlow1*, Kenneth A. Crawford1, Carol J. Bult2, Christopher Noakes3, Ido Sloma3, Erin R. Rudzinski4, Charles Keller1* 1 Children’s Cancer Therapy Development Institute, Beaverton, OR 97005 USA 2 The Jackson Laboratory, Bar Harbor, ME 04609 USA 3 Champions Oncology, One University Plaza, Hackensack, NJ 07601 USA 4 Seattle Children's Hospital, Seattle, WA 98105 USA * Correspondence: Noah E. Berlow, Children's Cancer Therapy Development Institute, 12655 SW Beaverdam Road-West, Beaverton OR 97005 USA, Tel (806) 370-8119, Fax (270) 675-3313, email [email protected] Charles Keller, Children's Cancer Therapy Development Institute, 12655 SW Beaverdam Road-West, Beaverton OR 97005 USA, Tel (801) 232-8038, Fax (270) 675-3313, email [email protected] Keywords: RET, alveolar rhabdomyosarcoma, endotypes in rhabdomyosarcoma, genetic profiles, transcriptomic profiles, drug screening, combination therapy word count (2333 words in main text, excluding Abstract, Methods, References and figure legends) 1 Downloaded from molecularcasestudies.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press Abstract Specific mutations in the RET proto-oncogene are associated with multiple endocrine neoplasia type 2A, a hereditary syndrome characterized by tumorigenesis in multiple glandular elements. In rare instances, MEN2A- associated germline RET mutations have also occurred with non-MEN2A associated cancers. One such germline mutant RET mutation occurred concomitantly in a young adult diagnosed with alveolar rhabdomyosarcoma, a pediatric and young adult soft-tissue cancer with a generally poor prognosis.
    [Show full text]
  • TBX3 Represses TBX2 Under the Control of the PRC2 Complex In
    Oh et al. Oncogenesis (2019) 8:27 https://doi.org/10.1038/s41389-019-0137-z Oncogenesis ARTICLE Open Access TBX3 represses TBX2 under the control of the PRC2 complex in skeletal muscle and rhabdomyosarcoma Teak-Jung Oh1, Abhinav Adhikari 2, Trefa Mohamad3, Aiysha Althobaiti2 and Judith Davie2 Abstract TBX2 and TBX3 function as repressors and are frequently implicated in oncogenesis. We have shown that TBX2 represses p21, p14/19, and PTEN in rhabdomyosarcoma (RMS) and skeletal muscle but the function and regulation of TBX3 were unclear. We show that TBX3 directly represses TBX2 in RMS and skeletal muscle. TBX3 overexpression impairs cell growth and migration and we show that TBX3 is directly repressed by the polycomb repressive complex 2 (PRC2), which methylates histone H3 lysine 27 (H3K27me). We found that TBX3 promotes differentiation only in the presence of early growth response factor 1 (EGR1), which is differentially expressed in RMS and is also a target of the PRC2 complex. The potent regulation axis revealed in this work provides novel insight into the effects of the PRC2 complex in normal cells and RMS and further supports the therapeutic value of targeting of PRC2 in RMS. Introduction phenotypes and the presence of myogenic markers such 4 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; Rhabdomyosarcoma (RMS) is the most common soft as myogenic regulatory factors (MRFs) , yet these factors tissue pediatric sarcoma, which is thought to largely arise appear to be inactive in RMS5. from the skeletal muscle lineage1. The more common The T-box family of transcription factors are highly form of the disease is the embryonal subtype (ERMS), conserved and related throughout all metazoan lineages.
    [Show full text]
  • Trim24-Regulated Estrogen Response Is Dependent on Specific Histone Modifications in Breast Cancer Cells
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 12-2012 TRIM24-REGULATED ESTROGEN RESPONSE IS DEPENDENT ON SPECIFIC HISTONE MODIFICATIONS IN BREAST CANCER CELLS Teresa T. Yiu Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Biochemistry Commons, Cancer Biology Commons, Medicine and Health Sciences Commons, and the Molecular Biology Commons Recommended Citation Yiu, Teresa T., "TRIM24-REGULATED ESTROGEN RESPONSE IS DEPENDENT ON SPECIFIC HISTONE MODIFICATIONS IN BREAST CANCER CELLS" (2012). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 313. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/313 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. TRIM24-REGULATED ESTROGEN RESPONSE IS DEPENDENT ON SPECIFIC HISTONE
    [Show full text]
  • Mechanisms of 4-Hydroxytamoxifen- Induced Apoptosis in Rhabdomyosarcoma Cells
    MECHANISMS OF 4-HYDROXYTAMOXIFEN- INDUCED APOPTOSIS IN RHABDOMYOSARCOMA CELLS by Kevin Min Chen A thesis submitted in conformity with the requirements for the degree of Master of Science Department of Medical Biophysics University of Toronto © Copyright by Kevin Min Chen (2011) Mechanisms of 4-hydroxytamoxifen-induced apoptosis in rhabdomyosarcoma cells Kevin Min Chen Master of Science Department of Medical Biophysics University of Toronto 2011 ABSTRACT Rhabdomyosarcoma (RMS) is a malignant soft-tissue sarcoma in children, accounting for about 40% of pediatric soft-tissue tumours. Five-year survival for metastatic RMS is only about 25%. Furthermore, there has been no significant improvement in RMS survival since 1975, pointing to a need for improved therapy. Previous work in our lab has shown that 4-hydroxytamoxifen (4OHT) leads to increased apoptosis and decreased viability in RMS cells. Expanding on this work, the current project aims to elucidate the mechanisms behind 4OHT-induced apoptosis in RMS cells, focusing on the roles of estrogen receptors (ER) and MAP kinases (MAPK). We found that: 1) 4OHT-induced apoptotic signaling was associated with increased MAPK phosphorylation, 2) Inhibition of MAPK protected cells against 4OHT, 3) Inhibition of ER also protected against 4OHT, and 4) ER inhibition blocked 4OHT- associated MAPK phosphorylation. ii ACKNOWLEDGEMENTS This work would not have been possible without the generous support and assistance received from the individuals and organizations below: Funding was provided in part by a Frederick Banting and Charles Best Canada Graduate Scholarship (CGS) - Master's Award, from the Canadian Institutes of Health Research (CIHR). Much gratitude goes to Dr. David Malkin for his guidance, and for cultivating a healthy and stimulating research environment.
    [Show full text]